Investigating Claims Involving ImmunSYS Inc.
The White Law Group is investigating potential securities claims involving broker dealers and financial advisors who may have unsuitably recommended ImmunSYS Inc. to investors.
According to Crunchbase, ImmunSYS Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products for late-stage metastatic cancers.
The company reportedly filed a form D to raise capital from investors in 2019. The total offering amount sold to 35 investors was purportedly $5,200,432.
Alternative investments such as this one, are generally speculative, high risk investments and due to these risks are often unsuitable for most investors. Despite the risks of investing in alternative investments, brokerage firms continue to push this type of investment because of the high commissions associated with their sale and creation.
Brokerage firms have a responsibility to adequately disclose all risks before selling any investment and must consider suitability factors such as age, financial needs, and risk tolerance to name a few. Firms that do not perform adequate due diligences on an investment or demonstrate a breach of fiduciary duty can be held accountable for losses incurred through FINRA arbitration.
Free Consultation with a Securities Attorney
If you are concerned about an investment in ImmunSYS Inc., the securities attorneys at The White Law Group may be able to help you by filing a complaint against your brokerage firm. Please call the offices at 888-637-5510 for a free consultation with a securities attorney.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois.
For more information on the firm, please visit https://www.whitesecuritieslaw.com.